KR102833111B1 - 칼슘 알파-케토글루타레이트의 제조 방법 - Google Patents

칼슘 알파-케토글루타레이트의 제조 방법 Download PDF

Info

Publication number
KR102833111B1
KR102833111B1 KR1020217010402A KR20217010402A KR102833111B1 KR 102833111 B1 KR102833111 B1 KR 102833111B1 KR 1020217010402 A KR1020217010402 A KR 1020217010402A KR 20217010402 A KR20217010402 A KR 20217010402A KR 102833111 B1 KR102833111 B1 KR 102833111B1
Authority
KR
South Korea
Prior art keywords
alpha
water
ketoglutarate
ketoglutaric acid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217010402A
Other languages
English (en)
Korean (ko)
Other versions
KR20210065120A (ko
Inventor
데이비드 유진 페레이라
케샤브 데오
Original Assignee
폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 filed Critical 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니
Publication of KR20210065120A publication Critical patent/KR20210065120A/ko
Application granted granted Critical
Publication of KR102833111B1 publication Critical patent/KR102833111B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217010402A 2018-09-25 2019-09-23 칼슘 알파-케토글루타레이트의 제조 방법 Active KR102833111B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736320P 2018-09-25 2018-09-25
US62/736,320 2018-09-25
PCT/US2019/052498 WO2020068705A1 (en) 2018-09-25 2019-09-23 Process of making calcium alpha-ketoglutarate

Publications (2)

Publication Number Publication Date
KR20210065120A KR20210065120A (ko) 2021-06-03
KR102833111B1 true KR102833111B1 (ko) 2025-07-10

Family

ID=69952136

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010402A Active KR102833111B1 (ko) 2018-09-25 2019-09-23 칼슘 알파-케토글루타레이트의 제조 방법

Country Status (18)

Country Link
US (1) US11802103B2 (OSRAM)
EP (1) EP3856166A4 (OSRAM)
JP (1) JP7499259B2 (OSRAM)
KR (1) KR102833111B1 (OSRAM)
CN (1) CN112955139B (OSRAM)
AU (1) AU2019350699B2 (OSRAM)
BR (1) BR112021005668A2 (OSRAM)
CA (1) CA3112205A1 (OSRAM)
CL (1) CL2021000728A1 (OSRAM)
CO (1) CO2021004529A2 (OSRAM)
IL (1) IL281761B2 (OSRAM)
MX (1) MX2021003482A (OSRAM)
MY (1) MY203278A (OSRAM)
PE (1) PE20211816A1 (OSRAM)
PH (1) PH12021550403A1 (OSRAM)
SG (1) SG11202102204PA (OSRAM)
TW (1) TWI863930B (OSRAM)
WO (1) WO2020068705A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN114105761B (zh) * 2021-11-19 2024-06-21 广东派特埃尔生物科技有限公司 一种α-酮戊二酸钠盐的合成工艺
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法
CN119977789A (zh) * 2025-02-12 2025-05-13 江苏惠利生物科技有限公司 一种离子交换树脂制备高纯度α-酮戊二酸钙的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776926A (en) 1955-08-04 1957-01-08 Eugene S Sharpe Preparation of alpha-ketoglutaric acid by serratia marcescens
US2917528A (en) 1956-08-24 1959-12-15 Victor Chemical Works Alkanolaminealkanephosphonic acids and salts thereof
US2841616A (en) * 1956-10-30 1958-07-01 Campbell Soup Co Process for the recovery of alpha-ketoglutaric acid
US3875304A (en) 1970-04-24 1975-04-01 Schlitz Brewing Co J Livestock feed composition and method of preparing the same
US4045585A (en) 1976-05-19 1977-08-30 Decel Corporation Flavored animal food compositions
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5646187A (en) 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US6306430B1 (en) 1998-04-16 2001-10-23 The Iams Company Process for decreasing adiposity using vitamin a as a dietary supplement
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP4169596B2 (ja) 2000-12-20 2008-10-22 アルコン、インコーポレイテッド 白内障を液化破壊により取り除くための溶液
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
US7589235B2 (en) * 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
PL368572A1 (en) 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
EP1778616A1 (en) 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
AU2005316295B2 (en) 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
US20060234250A1 (en) 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
WO2007001883A2 (en) 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
CA2628265A1 (en) 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
US8367121B2 (en) 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
PL379512A1 (pl) 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
EP2626077A3 (en) 2007-03-19 2013-11-20 Metaproteomics, LLC Compositions for promoting bone and joint health
CA2691746C (en) 2007-07-02 2016-02-02 Entress Ab Use of alpha-ketoglutarate in the treatment of hypertension
EP2033623A1 (en) 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
JP5406643B2 (ja) 2008-09-22 2014-02-05 日本合成化学工業株式会社 α−オキソカルボン酸の金属塩の製造方法
CN101759553A (zh) 2008-11-21 2010-06-30 扬子江药业集团北京海燕药业有限公司 α-酮酸钙的制备方法
DE102009016119A1 (de) 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
KR20130128018A (ko) 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
EA023913B1 (ru) 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
US20100303968A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
AU2010258356B2 (en) 2009-06-12 2017-01-19 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of brain diseases and conditions
ES2600909T3 (es) 2009-06-30 2017-02-13 Derman Biomedicine Co. Ltd. Composiciones que contienen berberina o análogos de la misma para tratar rosácea o trastornos de la piel relacionados con enrojecimiento de la cara
US9283257B2 (en) 2009-11-12 2016-03-15 Nox Technologies, Inc. Compositions comprising solanum tuberosum for lowering cytosolic NADH level to mimic calorie restriction
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
JP2014519483A (ja) 2011-04-18 2014-08-14 ネステク ソシエテ アノニム α−ヒドロキシイソカプロン酸を含有する栄養組成物
US9248185B2 (en) 2011-06-16 2016-02-02 President And Fellows Of Harvard College Methods of increasing satellite cell proliferation
CN102586347B (zh) * 2012-03-06 2014-04-09 江南大学 一种两阶段pH控制高产a-酮戊二酸的方法
US9532997B2 (en) 2012-04-03 2017-01-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell function
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
JP6029058B2 (ja) 2012-09-14 2016-11-24 国立研究開発法人農業・食品産業技術総合研究機構 シュウ酸カルシウムを含む氷核活性剤
AU2013318686B2 (en) 2012-09-19 2017-11-30 Grespo Ab Compositions for improvement of brain function
CN102976927A (zh) * 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
WO2014103475A1 (ja) 2012-12-27 2014-07-03 株式会社林原 アンチエイジング用皮膚外用組成物及びその製造方法
WO2014116985A1 (en) 2013-01-25 2014-07-31 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US9511057B2 (en) 2013-03-15 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating denervation-induced muscle atrophy
MY180761A (en) 2013-03-19 2020-12-08 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
WO2015123229A1 (en) 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
AU2015284409B2 (en) 2014-06-30 2020-06-25 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
CA3194562C (en) 2014-07-29 2026-03-17 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
WO2016019224A1 (en) 2014-07-31 2016-02-04 Indiana University Research And Technology Corporation Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy
CN104529755B (zh) * 2014-12-29 2016-01-06 精晶药业股份有限公司 一种从转化液中分离α-酮戊二酸的方法
WO2016161921A1 (en) 2015-04-06 2016-10-13 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
KR20180021784A (ko) 2015-06-10 2018-03-05 엘리시움 헬스, 인크. 피부병의 치료를 위한 니코틴아미드 리보시드 및 프테로스틸벤 조성물 및 방법
US20180193458A1 (en) 2015-07-08 2018-07-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
KR20190080875A (ko) 2016-09-30 2019-07-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
PL231635B1 (pl) 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
MX2017004010A (es) 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
WO2018200736A2 (en) 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan
US20200253907A1 (en) 2017-08-21 2020-08-13 The Regents Of The University Of California Compositions and Methods for Treating Neurodegenerative Diseases
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
WO2020086733A1 (en) 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
CA3142781A1 (en) 2019-06-10 2020-12-17 Buck Institute For Research On Aging Methods and compositions for altering senescence associated secretory phenotype
EP3980001B1 (en) 2019-06-10 2025-08-27 Ponce de Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate
US20230255912A1 (en) 2020-07-02 2023-08-17 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法

Also Published As

Publication number Publication date
SG11202102204PA (en) 2021-04-29
MX2021003482A (es) 2021-06-18
AU2019350699B2 (en) 2024-05-23
CL2021000728A1 (es) 2021-10-22
US20210371368A1 (en) 2021-12-02
TW202024013A (zh) 2020-07-01
CN112955139A (zh) 2021-06-11
TWI863930B (zh) 2024-12-01
US11802103B2 (en) 2023-10-31
AU2019350699A1 (en) 2021-04-08
MY203278A (en) 2024-06-21
CA3112205A1 (en) 2020-04-02
IL281761B1 (en) 2025-05-01
BR112021005668A2 (pt) 2021-06-22
JP2022502489A (ja) 2022-01-11
IL281761B2 (en) 2025-09-01
EP3856166A1 (en) 2021-08-04
EP3856166A4 (en) 2022-06-22
CN112955139B (zh) 2025-04-18
KR20210065120A (ko) 2021-06-03
PH12021550403A1 (en) 2021-10-04
JP7499259B2 (ja) 2024-06-13
CO2021004529A2 (es) 2021-04-30
WO2020068705A1 (en) 2020-04-02
PE20211816A1 (es) 2021-09-14
IL281761A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
TWI863930B (zh) 用於製備α-酮戊二酸鈣之方法
Tager et al. 2-Aminonorbornane-2-carboxylic acid. Preparation, properties, and identification of the four isomers
US8969563B2 (en) Calcium salt of pyrroloquinoline quinone
JP2721434B2 (ja) ヘテロ環ビス（フォスフォン酸）誘導体１水和物の新規結晶
US10100055B2 (en) Imidazopyrroloquinoline salt, method for producing the same, medicament, cosmetic, and food
OA12166A (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetestherewith.
HK40053335A (en) Process of making calcium alpha-ketoglutarate
Roth et al. Analogs of pteroylglutamic acid. VIII. 4-Alkoxy derivatives
HK40053335B (zh) 用於制备α-酮戊二酸钙的方法
PL89632B1 (OSRAM)
EP0158879B1 (en) Compounds having cardiotrophic activity, a process for the preparation thereof and pharmaceutical compositions therefrom
JPS6014026B2 (ja) パンテテイン−ｓ−スルホン酸及びその塩の製造法
JPS61143345A (ja) メナジオンコリン重亜硫酸付加物及びその製法
US2773872A (en) Dihydroorotic acid
SU1397441A1 (ru) Способ получени 1,8-нафтсультама
JP2000510486A (ja) α−トコフェロール−４−アミノ安息香酸エステル化合物及びその製造方法
US5011974A (en) Process for the preparation of derivative of 2-diethylamino-1-methylethyl-1-hydroxy-(bicyclohexyl)-2-carboxylate
KR100461572B1 (ko) Ｌ-카르니틴 칼슘 염과 이의 제조방법
WO2024235167A1 (zh) 一种吡唑并吡嗪类化合物及其晶型的制备方法
SU1558924A1 (ru) Способ получени оксидов алкил-ди-( @ -карбоксифенил)арсинов
JPH03170486A (ja) 新規なオキサゾピロロキノリン化合物
CZ278017B6 (en) Process for preparing crotonbetaine hydrochloride
KR910003184B1 (ko) 프롤린 유도체의 제조방법
SK280602B6 (sk) Viacjadrové komplexné zlúčeniny horčíka s aminodik
JPH03170484A (ja) 新規なオキサゾピロロキノリン化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)